Phase II trial of induction @entity136 and @entity3003 followed by conformal thoracic radiation to 74 Gy with weekly @entity1311 and XXXX in unresectable @entity5 .

@entity1 @entity5 @entity3003 @entity1149 @entity1311 @entity136
INTRODUCTION: The survival for @entity1 with locally advanced, unresectable @entity1149 receiving standard of care concomitant chemoradiation remains disappointingly low. A reduction in both local and distant recurrence is needed to improve @entity1 ' outcome. Performing molecular studies on serially collected @entity5 specimens may result in a better selection of therapeutic options. METHODS: We conducted a phase II single-institution trial of two cycles of induction chemotherapy with @entity136 and @entity3003 followed by high-dose conformal radiation concomitant with weekly @entity1311 and @entity3003 in 39 @entity1 . The trial required a dedicated @entity5 biopsy before treatment initiation. In addition, @entity5 biopsies were requested, if safely feasible, before initiation of chemoradiation and 2 months after completion all therapy. RESULTS: Induction chemotherapy was well tolerated, and 38 @entity1 proceeded with chemoradiation. The mean delivered radiation dose was 70.2 Gy, 23 @entity1 received the full dose of 74 Gy, and 19 @entity1 completed all treatment on schedule without dose reductions or delays. Median overall and progression-free survivals were 22.7 and 14.3 months, respectively. A total of 82 procedures, including 46 transthoracic core needle biopsies, were performed. Thirteen @entity1 had all three serial @entity5 biopsies. Three of these procedures resulted in complications that required an intervention; all for the treatment of a biopsy-induced pneumothorax. CONCLUSIONS: We conclude that induction @entity136 / @entity3003 followed by concurrent @entity1311 / @entity3003 with conformal radiation to 74 Gy is safe and tolerable with promising efficacy. We demonstrated that dedicated and serial @entity5 collections are safe, feasible, and acceptable for @entity1 with @entity1149 .
